User:Mr. Ibrahem/Panobinostat

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Panobinostat
Clinical data
Trade namesFarydak
Other namesLBH-589
AHFS/Drugs.comMonograph
License data
Routes of
administration		By mouth (capsules)
Drug classHistone deacetylase inhibitor (HDAC inhibitor)[1]
Legal status
Legal status
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability21%[2]
Protein binding90%[2]
MetabolismCYP3A (40%), CYP2D6, CYP2C19[2]
Elimination half-life37 hours[2]
ExcretionFecal (44–77%), renal (29–51%)[2]
Identifiers
  • (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
Chemical and physical data
FormulaC21H23N3O2
Molar mass349.434 g·mol−1
3D model (JSmol)
  • O=C(NO)\C=C\c1ccc(cc1)CNCCc3c2ccccc2[nH]c3C
  • InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+ ☒N
  • Key:FPOHNWQLNRZRFC-ZHACJKMWSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Panobinostat, sold under the brand name Farydak, is a medication used to treat multiple myeloma.[1] It is used when at least two other treatments have failed.[1] It is taken by mouth.[1] It is used together with bortezomib and dexamethasone.[1]

Common side effects include diarrhea, tiredness, nausea, swelling, fever, weight loss, high magnesium, low calcium, low potassium, low white blood cells, and low platelets.[3] Other side effects may include bleeding, QT prolongation, and infections.[3] Use during pregnancy may harm the baby.[3] It is a histone deacetylase inhibitor (HDAC inhibitor).[1]

Panobinostat was approved for medical use in the United States and Europe in 2015.[3][4] In the United Kingdom six doses costs the NHS about £4,700 as of 2021.[1] This amount in the United States costs about 15,000 USD.[5]

References[edit]

  1. ^ a b c d e f g h i BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 979. ISBN 978-0857114105.
  2. ^ a b c d e "Panobinostat Package Insert" (PDF). Archived (PDF) from the original on 2021-04-10. Retrieved 2021-07-07.
  3. ^ a b c d e "Panobinostat Monograph for Professionals". Drugs.com. Archived from the original on 9 July 2021. Retrieved 26 October 2021.
  4. ^ "Farydak product details". European Medicines Agency. Archived from the original on 2018-06-20. Retrieved 2022-03-14.
  5. ^ "Farydak Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 11 May 2021. Retrieved 26 October 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Panobinostat&oldid=1222185914"